HouseofCards; I believe your pithy post underscores the most compelling basis to favor a BP partnership or BO at a discounted price over going it alone: mitigating the risk that the FDA will prevent LL from being approved this decade.
To those who would shrug off such a concern as ridiculous, I would cite the FDA's insistence on the ludicrous, self defeating covid trial protocol requiring LL dosing on days 0 and 7 with patient readouts on day 28, its unwillingness to immediately facilitate a new trial with a 0/7/14 protocol after CYDY published the 82% mortality improvement over SOC as of day 14 while millions were dying, the unprecedented issuance of the FDA letter, and a 2 year safety hold, including several goal post changes, for one of the safest drugs ever developed.
Perhaps all of the above were just conventional bureaucratic responses to Nader and his baggage. And all may be well, now that Dr Jay has taken the helm. This may well be true. But should CYDY and its shareholders risk the company's and LL's survival on the FDA's future good faith given its track record with CYDY and LL?
I, like so many other board members, am disdainful of BP and all of its predatory, greedy practices. Moreover, going it alone would be far more beneficial to shareholders, and hopefully patients, if Dr Jay and his small staff could get LL approved and available in a reasonable timeframe. But many substantial risks will be involved in such an undertaking. For all its warts, the right BP could mitigate those risks substantially.
Just something to consider.
To those who would shrug off such a concern as ridiculous, I would cite the FDA's insistence on the ludicrous, self defeating covid trial protocol requiring LL dosing on days 0 and 7 with patient readouts on day 28, its unwillingness to immediately facilitate a new trial with a 0/7/14 protocol after CYDY published the 82% mortality improvement over SOC as of day 14 while millions were dying, the unprecedented issuance of the FDA letter, and a 2 year safety hold, including several goal post changes, for one of the safest drugs ever developed.
Perhaps all of the above were just conventional bureaucratic responses to Nader and his baggage. And all may be well, now that Dr Jay has taken the helm. This may well be true. But should CYDY and its shareholders risk the company's and LL's survival on the FDA's future good faith given its track record with CYDY and LL?
I, like so many other board members, am disdainful of BP and all of its predatory, greedy practices. Moreover, going it alone would be far more beneficial to shareholders, and hopefully patients, if Dr Jay and his small staff could get LL approved and available in a reasonable timeframe. But many substantial risks will be involved in such an undertaking. For all its warts, the right BP could mitigate those risks substantially.
Just something to consider.
19
